Daryl Pritchard, PhD

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and improve patient outcomes in oncology.

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.

Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.

The Bonnie Addario Lung Cancer Foundation has developed a registry that can serve as a repository for data on patients with lung cancer-a means to empower patients and assist care providers to deliver personalized medicine in a patient-centered manner.

This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.